Log In
Print
BCIQ
Print
Print this Print this
 

Mylotarg, gemtuzumab ozogamicin

Also known as: CMA-676

  Manage Alerts
Collapse Summary General Information
Company Pfizer Inc.
DescriptionCombination of calicheamicin with a humanized mAb that targets CD33-expressing cancer cells
Molecular Target CD33
Mechanism of ActionAntibody-drug conjugate
Therapeutic ModalityBiologic: Antibody-drug conjugate
Latest Stage of DevelopmentMarketed
Standard IndicationAcute myelogenous leukemia (AML)
Indication DetailsTreat acute myelogenous leukemia (AML); Treat CD33-positive relapsed acute myelogenous leukemia (AML); Treat refractory acute myelogenous leukemia (AML)
Regulatory Designation

Partner

UCB Group


 Product Details
 Archive Items are loading loading
Get a free BioCentury trial today